Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M23-784: Subcutaneous risankizumab induction therapy in moderately to severely active Crohn's disease
jRCT2061230105Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (5 arms), sponsored by AbbVie Inc. Primary endpoints: CDAI clinical remission at Week 12 and Endoscopic response at Week 12. Started Mar 2024; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2061230105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230105.